- Home
- ZENV vs PLRX Comparison
ZENV vs PLRX Comparison
Compare ZENV & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- PLRX
- Stock Information
- Founded
- ZENV 2005
- PLRX 2015
- Country
- ZENV Brazil
- PLRX United States
- Employees
- ZENV N/A
- PLRX N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- PLRX Health Care
- Exchange
- ZENV Nasdaq
- PLRX Nasdaq
- Market Cap
- ZENV 146.3M
- PLRX 165.5M
- IPO Year
- ZENV 2021
- PLRX 2020
- Fundamental
- Price
- ZENV $2.15
- PLRX $3.08
- Analyst Decision
- ZENV
- PLRX Buy
- Analyst Count
- ZENV 0
- PLRX 10
- Target Price
- ZENV N/A
- PLRX $14.86
- AVG Volume (30 Days)
- ZENV 121.2K
- PLRX 3.4M
- Earning Date
- ZENV 11-18-2024
- PLRX 02-26-2025
- Dividend Yield
- ZENV N/A
- PLRX N/A
- EPS Growth
- ZENV N/A
- PLRX N/A
- EPS
- ZENV N/A
- PLRX N/A
- Revenue
- ZENV $173,594,726.00
- PLRX N/A
- Revenue This Year
- ZENV $28.66
- PLRX N/A
- Revenue Next Year
- ZENV $2.98
- PLRX N/A
- P/E Ratio
- ZENV N/A
- PLRX N/A
- Revenue Growth
- ZENV 23.49
- PLRX N/A
- 52 Week Low
- ZENV $1.12
- PLRX $2.43
- 52 Week High
- ZENV $3.88
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- ZENV 40.78
- PLRX 22.51
- Support Level
- ZENV $1.87
- PLRX $2.92
- Resistance Level
- ZENV $2.45
- PLRX $3.16
- Average True Range (ATR)
- ZENV 0.21
- PLRX 0.85
- MACD
- ZENV -0.05
- PLRX -0.39
- Stochastic Oscillator
- ZENV 37.53
- PLRX 6.22
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.